UGI endoscopy(esophagogastroduodenoscopy) is the main diagnostic modality for direct visualization ,real time assessment and interpretation of findings encountered. The evaluation of esophagogastroduodenoscopy (EGD) quality measures encompasses several categories, such as structure, procedure, result, and adverse events. The peri-EGD period procedures fall under the procedural area, which is primarily concerned with preventing and minimising missed diagnoses.
. More aid in the identification and characterisation of gastrointestinal mucosal lesions is provided by endoscopes equipped with improved imaging technologies, such as multiband or narrow-band imaging (NBI). Despite these advancements of technological aspects, the unclean mucosal surface of the stomach can make these high-end pieces of equipment virtually useless To visualize properly and diagnose accurately there should be clear visibility of mucus apart from operator experience. Since the stage at diagnosis of upper gastrointestinal cancer is a major factor in survival, early detection is essential in improving the prognosis of patients the main factors responsible for hinderance of mucosal visibility are mucus foam and bubbles, which requires additional care for the clearance to enhance the vision and also decrease endoscopy duration by alleviating the need of repeated flushing and suctioning during endoscopy. The froth and bubbles are made of mucous secretions mixed with gastric juice and bile. Simethicone (polydimethylsiloxane and silicon dioxide) has been proven to be a promising defoaming agent as an endoscopic premedication in removing bubbles . Simethicone works by reducing the surface tension of air bubbles, and releases the trapped air by causing small bubbles to coalesce and collapse . N-acetylcysteine (nac), a mucolytic agent, has also been used as premedication acts by removing the mucous overlying the gastrointestinal mucosa 4-point scale described by Basford et al
1. No adherent mucus and clear views of the mucosa.
2. A thin coating of mucus that did not obscure views of the mucosa.
3. Some mucus/bubbles partially obscuring views of the mucosa (i. E. A small mucosal lesion might be missed without flushing
4. Heavy mucus/bubbles obscuring views of the mucosa (i. E. Extensive flushing is needed to avoid missing small mucosal lesions)

Start Date01 Nov 2024

Sponsor / Collaborator

Asian Institute of Gastroenterology Pvt Ltd.

ChiCTR2400091746 / SuspendedPhase 4IIT

Efficacy of simethicone in the treatment of abdominal distension after colonoscopy: a multi-center, single-blinded, randomized controlled study

Start Date01 Nov 2024

Sponsor / Collaborator

Zhongshan Hospital Fudan University

CTRI/2024/10/074635 / Not yet recruitingPhase 4IIT

Effectiveness of N acetyl cysteine and Simethicone to improve mucosal visibility during GI endoscopy-An interventional study - NA

Start Date09 Oct 2024

Sponsor / Collaborator-

100 Clinical Results associated with Simethicone

100 Translational Medicine associated with Simethicone

100 Patents (Medical) associated with Simethicone

349

Literatures (Medical) associated with Simethicone

01 Nov 2024·Advances in Therapy

Evaluation of Aluminum and Magnesium Absorption Following the Oral Administration of an Antacid Suspension Containing Magaldrate in Healthy Women Under Fed Conditions

Article

Author: do Prado Assunção, Leandro ; Arbeláez Quintero, Isaac ; Calafatti Carandina, Silvana Aparecida ; Iorgatchof Xavier, Kamila ; Cruz Palacios, Maria Juliana ; Burgos Castillo, Maria Juliana

INTRODUCTIONAntacids are commonly used during pregnancy, and they are approved for the relief of symptoms of gastroesophageal reflux disease (GERD) during pregnancy. However, there are no reports of the quantification of the absorption of aluminum and magnesium in the antacid magaldrate in women. The aim of this study was to quantify the rate and magnitude of absorption of aluminum and magnesium in magaldrate.METHODSAn open-label, controlled, randomized, one-treatment study with a two-group design was conducted in healthy women in a fed state. The volunteers had a standard breakfast, and 30 min later, they were given a single-medication sachet containing 500 mg of sodium alginate, 267 mg of sodium bicarbonate, 800 mg of magaldrate, and 120 mg of simethicone (group A, n = 8) or no medication (group B, n = 2). Blood samples were obtained 36 h before and up to 12 h after antacid administration. The method used for quantification was inductively coupled plasma-mass spectrometry.RESULTSThere was no absorption of aluminum in any of the blood samples from the healthy volunteers who received the drug or in those from the control group. Magnesium was detected at normal concentrations.CONCLUSIONThese findings suggest that the use of this antacid is safe and without risk in healthy women, including pregnant women.CLINICAL TRIAL REGISTRATIONClinicaltrials.gov registration: NCT06367452.

04 Oct 2024·Journal of Medical Microbiology

Effect of simethicone on the bactericidal efficacy of a high-level disinfectant

Article

Author: Anderson, Gregory G. ; Weeks, Jon W. ; Haugen, Shanil P. ; Pandey, Ruchi ; Segars, Katharine ; Sanchez, Anastacia M.

Introduction. Simethicone is an over-the-counter product that is frequently used by clinicians during endoscopic procedures to reduce foaming and improve visualization. Published studies have found simethicone residue on endoscopes after cleaning and disinfecting the devices as per the manufacturer’s instructions. Some literature suggests that simethicone residue may reduce disinfection efficacy and increase the risk of patient infections.Gap Statement. However, there appears to be a lack of direct evidence in the literature to either disprove this or correlate simethicone presence with an increased microbial risk.Aim: Research was conducted to evaluate the in vitro impact of simethicone on disinfection efficacy.Methodology. Bacteria were grown in a microtitre plate assay in the presence of a range of simethicone concentrations and then treated with a disinfectant. Bacterial growth was assessed by spotting each microtitre well onto an agar plate.Results. The results demonstrated that, under the conditions tested, simethicone did not reduce the efficacy of Cidex ortho-phthalaldehyde disinfectant, which demonstrated at least a 6-log unit reduction in bacterial viability. Additional experiments showed that direct exposure to 66 mg ml−1 of simethicone reduced bacterial viability.Conclusion. These results indicate that simethicone may not reduce the bactericidal efficacy of disinfectant during reprocessing, under certain conditions.

01 Oct 2024·Indian Journal of Gastroenterology

Pre-medication with simethicone and N-acetyl cysteine for improving mucosal visibility during upper gastrointestinal endoscopy: A randomized controlled trial

Article

Author: Manchu, Chaithanya ; Reddy, Praveen ; Goud, Rajesh ; Darisetty, Santosh ; Tandan, Manu ; Gupta, Rajesh ; Basha, Jahangeer ; Nabi, Zaheer ; Reddy, Palle Manohar ; Reddy, D Nageshwar ; Vamsi, Mohan ; Rao, Guduru Venkat ; Sayyed, Mahiboob ; Reddy, Rithesh

BACKGROUND AND AIMDiagnostic performance of esophagogastroduodenoscopy (EGD) may be compromized due to adherent mucus and foam. In this study, we aimed at assessing the impact of premedication on mucosal visibility during endoscopy.METHODSThis is a double-blinded (patient and investigator), randomized trial conducted at a tertiary care centre. Patients were randomized into four groups: A (water), B (simethicone [S]), C (N-acetyl cysteine [NAC]), D (S + NAC). Premedication solutions were administered 10-30 minutes before endoscopy and mucosal visibility graded from 1 (best) to 4 (worst) (1 best, 4 worst). Total mucosal visibility scores (TMVS) from six sites ranged from 6 (best) to 24 (worst) points. The primary outcome of study was comparison of TMVS between simethicone and combination (S + NAC) premedication groups. Secondary outcomes were adverse events and impact of endoscopy timing on TMVS.RESULTSTotal 800 patients (39 years, 68.8% males) were randomized into four groups. Median TMVS were significantly lower in groups B (7 [6-8]) and D (8 [6-9]) as compared to A (11 [9-13]) and C (10 [8-12]). Proportion of cases with adequate gastric mucosal visibility (score < 7) was 26% in group A, 71% in group B, 36% in group C and 79% in group D. There was no difference in TMVS in groups A and C (p = 0.137). TMVS were significantly lower in late (> 20-30 minutes) vs. early (10-20 minutes) endoscopy sub-group (8 [7-11] vs, 9 ([7-11], p = 0.001). However, TMVS were similar between group B and group D in early endoscopy group (p = 0.451). There was no significant difference in the lesion detection rate among the different premedication drugs (p > 0.05).CONCLUSIONSPremedication with simethicone or combination (simethicone and NAC) significantly improves mucosal visibility during EGD. If early endoscopy is indicated, simethicone provides similar mucosal visibility and may be an effective alternative to combined premedication.TRIAL REGISTRATIONNCT05951712.

News (Medical) associated with Simethicone

08 Apr 2024

·www.prnewswire.com

Wonderbelly Expands its Suite of Digestive Health Medicines with Launch of Bloat + Gas Relief

AUSTIN, Texas, April 8, 2024 /PRNewswire/ -- Wonderbelly, known for its effective digestive medicine, clean* ingredients and tasty flavors, today announced the launch of its latest product: Wonderbelly Bloat + Gas Relief. The launch marks a considerable milestone in Wonderbelly's goal to become the go-to brand for all things digestive health as the company grows into a second category of digestive medicine. Wonderbelly Bloat + Gas Relief is now available to consumers at Target, on Target.com and Amazon.com. Continue Reading Wonderbelly Expands its Suite of Digestive Health Medicines with Launch of Bloat + Gas Relief Post this Wonderbelly launches Bloat + Gas Relief in two delicious flavors, Strawberry Shortcake and Mango Smoothie. Wonderbelly products offer the same highly effective relief as leading medicine brands with a focus on clean ingredients that are Non-GMO and Clean Label Project Certified. Wonderbelly Bloat + Gas Relief has been expertly formulated to effectively combat symptoms like bloating, gas discomfort, abdominal pressure, and associated fullness. Boasting extra strength with 125mg of Simethicone, the company's new medicine comes in two enticing flavors: Strawberry Shortcake and Mango Smoothie. "From the very beginning, we've been committed to reimagining the digestive health experience so that people can feel good about feeling good. After launching Wonderbelly Antacid last year, we're thrilled to expand into a new digestive category to offer consumers highly effective bloat and gas relief in two delicious flavors we know people will love," says Wonderbelly founder Lucas Kraft. "Ultimately, Bloat + Gas represents a natural progression for Wonderbelly and a direct response to consumer demand for medicine that reflects their modern values. We've worked hard with our retail partners to identify customer needs and are proud to deliver a solution that gives them exactly what they're looking for." Building upon the success of Wonderbelly Antacid, which has rapidly become a consumer favorite with over one thousand five-star reviews, Wonderbelly Bloat + Gas Relief further cements Wonderbelly's role as a trailblazer in the rapidly evolving segment of modern digestive health medicine. "It's great to see Wonderbelly really resonate with consumer demand in the medicine space, particularly with trends towards clean ingredients and more sustainable packaging," says brain-gut expert Emeran Mayer, MD (emeranmayer.com). "I'm excited to continue to support Wonderbelly as they expand their offerings to provide relief for a range of digestive health symptoms." Wonderbelly is committed to using recyclable packaging, with bottles made solely of metal to reduce the use of plastic. Produced by one of the leading OTC manufacturers in the United States, Wonderbelly's products and novel packaging undergo rigorous testing, adhering to the stringent standards set for major pharmaceutical products. Wonderbelly can be found in Target and at retail locations across the country, like Wegmans, Meijer, Kroger, Fred Meyer, Fresh Thyme, Giant Eagle*, Raley's*, Harris Teeter, Central Market, Erewhon, Earth Fare, MOM's Organic. *Wonderbelly defines clean medicine as formulated using pharmaceutical active ingredients with inactive ingredients that are Clean Label Project-Certified, vegan, Non-GMO, and free of artificial dyes, artificial sweeteners, talc, titanium dioxide, parabens, gluten, and dairy. For more information about Wonderbelly, please visit Wonderbelly.com For visual assets, please see Dropbox PR Contact: [email protected] About Wonderbelly Wonderbelly™ is a digestive health medicine company founded by brothers Lucas and Noah Kraft. Wonderbelly makes effective and tasty digestive health medicine free from dyes, artificial sweeteners, talc, titanium dioxide, and genetically modified ingredients. Wonderbelly offers two products, Wonderbelly Antacid™ and Wonderbelly Bloat + Gas Relief™, in an assortment of delicious flavors. The company is committed to using recyclable packaging, including metal bottles and compostable on-the-go pouches, to reduce the use of plastic. SOURCE Wonderbelly

11 May 2021

·www.globenewswire.com

Gastrointestinal Drugs Market Growth Sturdy at 4.9% CAGR to

Pune, India., May 10, 2021 (GLOBE NEWSWIRE) -- Gastrointestinal Drugs Market: Key InsightsAccording to our new research study on “Gastrointestinal Drugs Market to 2027 – Global Analysis and Forecast – by Drug Class, Route of Administration, Application, and Distribution Channel,” the Gastrointestinal Drugs Market Size was valued at US$ 49,043.38 million in 2019 and is projected to reach US$ 71,300.28 million by 2027; it is expected to grow at a CAGR of 4.9% during 2020–2027. The extensive rise in COVID-19 infection fuels growth of the market. However, low awareness associated with gastrointestinal disorders in low-income economies is restricting the market growth. Gastrointestinal Drugs Market: Competition Landscape and Key DevelopmentsSanofi; GlaxoSmithKline plc; Johnson and Johnson Services, Inc.; Bausch Health; AstraZeneca; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Bayer AG; Celltrion Healthcare Co., Ltd.; and Lexicon Pharmaceuticals, Inc. are among the key companies operating in the gastrointestinal drugs market. Leading players are focusing on the expansion and diversification of their market presence and acquisition of new customer base, thereby tapping prevailing business opportunities. In January 2020, AstraZeneca recovered the global rights to brazikumab (formerly MEDI2070), a monoclonal antibody targeting IL23, from Allergan. Brazikumab is currently in a Phase IIb/III program in Crohn’s disease (CD) and a Phase IIb trial in ulcerative colitis (UC). AstraZeneca and Allergan will terminate their existing license agreement and all rights to brazikumab will revert to AstraZeneca. The transaction is expected to complete in the first quarter of 2020. Get Exclusive Sample Pages of Gastrointestinal Drugs Market - COVID-19 Impact and Global Analysis with Strategic Insights at In 2019, North America dominated the global gastrointestinal drugs market. The market growth in the region is attributed to increase in incidence of gastrointestinal diseases due to change in lifestyle, government support for prevention and treatment of gastrointestinal diseases, presence of well-developed healthcare infrastructure, growth of pharmaceutical industry, reimbursement coverage, and industry giants. Moreover, according to the National Health Interview Survey, in 2018, about 14.8 million people in the US were diagnosed with ulcers. Furthermore, the National Ambulatory Medical Care Survey: 2016 reported that around 22.4 million patients visited a physician’s office for digestive diseases, and about 8.3 million emergency department visits were for digestive diseases. Also, US Food and Drug Administration (FDA) approvals in the US are likely to favor the growth of the market. For instance, in May 2020, the US FDA approved Qinlock (ripretinib) tablets as a fourth-line treatment for advanced gastrointestinal stromal tumor (GIST). Furthermore, developments by the market players in this industry is likely to favor market growth. Based on drug class, the gastrointestinal drugs market is segmented into acid neutralizers, antidiarrheal and laxatives, anti-inflammatory drugs, antiemetic and antinauseants, biologics, and others. The acid neutralizers segment held the largest share of the market in 2019. Based on route of administration, the gastrointestinal drugs market is segmented into oral and parenteral. The oral segment held larger share of the market in 2019 and is estimated to register higher CAGR in the market during the forecast period. Based on application, the gastrointestinal drugs market is segmented into inflammatory ulcerative colitis, Crohn's disease, irritable bowel syndrome, gastroenteritis, celiac disease, and others. The inflammatory ulcerative colitis segment held the largest share of the market in 2019. Based on distribution channel, the gastrointestinal drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment held the largest share of the market in 2019, and it is estimated to register the highest CAGR in the market during the forecast period. Download Sample PDF Brochure of Gastrointestinal Drugs Market Growth Research Report at The COVID-19 outbreak started in December 2019 in Wuhan (China), and it has spread to ~100 countries across the world, with the World Health Organization (WHO) stating it as a public health emergency. The global impacts of COVID-19 are being felt across several markets. Although the healthcare sector had witnessed SARS, H1N1, and other outbreaks in the last few years, the severity of the COVID-19 has made the situation more complicated due to its mode of transmission. North America has been witnessing a growing number of COVID-19 cases since its outbreak. For instance, according to Worldometer, the number of cases increased to 7,679,908 with 215,039 deaths reported in the US as of October 06, 2020. The cases are also increasing in Mexico and Canada. In Mexico, the cases have reached 761,665, with 79,088 deaths. Similarly, in Canada, there are about 168,960 COVID-19 cases, with 9,504 deaths reported so far. Several companies are cutting their clinical trial activities in response to the COVID-19 pandemic. For instance, slashing clinical trial activity will affect the timelines for Eli Lilly's late-phase trials of mirikizumab in gastrointestinal indications. According to their listings on ClinicalTrials.gov., the phase 3 trials for mirikizumab in Crohn’s disease and ulcerative colitis have primary completion dates ranging from September 2020 to late 2023, which can be a confirmed delay. However, in long run, the demand is expected to increase. For instance, according to the estimates reported by Ironwood Pharmaceutical, the demand for prescription drug product LINZESS—indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation—is expected to increase by 11% from the demand in 2019. Therefore, the growing demand for the constipation treatment in North America in long-term period is likely to boost the growth of the gastrointestinal drugs market. Buy Copy of Gastrointestinal Drugs Market Research Study at Gastrointestinal Drugs Market: Segmental OverviewBased on drug class, the gastrointestinal drugs market is segmented into acid neutralizers, antidiarrheal and laxatives, anti-inflammatory drugs, antiemetic and antinauseants, biologics, and others. The acid neutralizers segment held the largest share of the market in 2019. Antacids are over-the-counter (OTC) medications that neutralize stomach acid and help in relieving heartburn, sour stomach, acid indigestion, and stomach upset. They are available as a liquid or chewable tablet. Some antacids also contain simethicone, an ingredient that helps body in relieving gas. Some antacids contain ingredients that can cause diarrhea, such as magnesium, or constipation, such as aluminum. Based on route of administration, the market is segmented into oral and parenteral. The oral segment held larger share of the market in 2019 and is estimated to register higher CAGR in the market during the forecast period. Based on application, the market is segmented into inflammatory ulcerative colitis, Crohn's disease, irritable bowel syndrome, gastroenteritis, celiac disease, and others. The inflammatory ulcerative colitis segment held the largest share of the market in 2019. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment held the largest share of the market in 2019 and is estimated to register the highest CAGR in the market during the forecast period. About Us:The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us:If you have any queries about this report or if you would like further information, please contact us: Contact Person: Sameer JoshiE-mail: sales@theinsightpartners.comPhone: +1-646-491-9876 Press Release -

AntibodyAcquisition

100 Deals associated with Simethicone

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Abdomen distended	US	-	01 Jan 1952
Flatulence	CN	BERLIN-CHEMIE AG	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Abdomen distended	Phase 2	RU	Abbott Laboratories	27 Nov 2020
Abdominal Pain	Phase 2	RU	Abbott Laboratories	27 Nov 2020
Irritable Bowel Syndrome	Phase 2	RU	Abbott Laboratories	27 Nov 2020
Gastrointestinal Hemorrhage	Phase 2	US	Mayo Clinic	30 Apr 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05175131 (CTgov)	Phase 3	Abdominal Pain \| Irritable Bowel Syndrome	465	Simethicone+Mebeverine (Mebeverine+Simethicone Combination)	xzzqsugolb(zsczenqfba) = kbdhabampl nqpiigqxog (jlllkwverw, twzpcjgbff - ckwukvjpbi) View more	-	03 Jan 2024
				Mebeverine (Mebeverine)	xzzqsugolb(zsczenqfba) = jahkqpxitg nqpiigqxog (jlllkwverw, raalchhike - jckamwmpyu) View more
NCT05951712 (Pubmed \| Indian J Gastroenterol)	Not Applicable	-	800	simethicone (Water)	wgrpmggbol(arnmsflzua) = veocrgmamx tqstmkhwtb (iwzzjobzah, 9 - 13)	Positive	18 Oct 2023
				Simethicone	wgrpmggbol(arnmsflzua) = uzglgwsxfk tqstmkhwtb (iwzzjobzah, 6 - 8)
PREMEDICATION WITH SIMETHICONE (UEGW2021)	Not Applicable	-	110	Simethicone 200mg	pkflbiblrk(pmqcdzgwvp) = klcnbguamd ibmwgbfatz (voeumjbazm ) View more	Positive	02 Oct 2021
				Placebo	pkflbiblrk(pmqcdzgwvp) = cpidkyujnb ibmwgbfatz (voeumjbazm ) View more
NCT03119168 (CTgov)	Phase 4	Adenoma	268	Simethicone Solution (Simethicone Solution + Polyethylenglycol)	ylddquiqbh(cnkcsbdabd) = banqlmrjkg wlwiokyfqc (vynyjfusay, xiavfkkgsp - rdaviazkva) View more	-	05 Jun 2019
				Polyethylenglycol (Polyethylenglycol)	ylddquiqbh(cnkcsbdabd) = jexjckptpz wlwiokyfqc (vynyjfusay, bweimunaez - xupivdqkif) View more
NCT02217982 (IIT9, CTgov)	Phase 4	Multiple Sclerosis, Relapsing-Remitting	5	Peanut Butter+Simethicone+Loperamide	dsxkioutdm(dodpgcpzrc) = ratsryzbic dhudgehcdy (ytzenjzzru, hxbavvohhy - kkccfzagkn) View more	-	06 Jan 2017
NCT01312038 (CTgov)	Phase 2	Functional disorder \| Otitis Media	25	Placebo (Placebo)	yiqcaciqiq(xbfeamrtzu) = jrjcmkdiis mfjtfnjptw (exfpndyhuu, tciozinpgv - pfqtwfnfji) View more	-	27 Jun 2016
				Simethicone (Simethicone)	gbrtqttard(ycadzgiblf) = rkkbghpkql fvijtwoscc (udyogwktdw, veezvhqkfu - qgghosimax) View more
NCT02555228 (CTgov)	Phase 2/3	Gastric mucosal lesion	54	Simethicone (Simethicone Premedication)	dfrwcltupg(cyemhwcddb) = cblvojjitk ybjfbfrfyd (ygysohkcpm, kgemdglcpl - lboxomzpkq) View more	-	15 Mar 2016
				Water (Placebo)	dfrwcltupg(cyemhwcddb) = unnrktpuye ybjfbfrfyd (ygysohkcpm, xenvtwyugj - qfenqhqqoc) View more
UEGW2014	Not Applicable	Irritable Bowel Syndrome	-	Pinaverium bromide 100 mg + simethicone 300 mg	ebeaujpdau(cutlyssgis) = uumxrotnyh dolztkodxx (rlhiixzpgb )	-	01 Oct 2014
NCT01653171 (Pubmed \| World J Gastroenterol)	Phase 4	-	230	Sodium phosphate plus simethicone	lgvnpvmvwk(xqyeidoors) = qivhzegrjg cgaaotrffk (speojsfejp ) View more	-	28 Jun 2009
				Sodium phosphate plus placebo	lgvnpvmvwk(xqyeidoors) = jlgofkxwqo cgaaotrffk (speojsfejp ) View more
NCT01653171 (Pubmed \| J Zhejiang Univ Sci B)	Phase 4	Intestinal preparation	230	PEG solution	(edgihoxqse) = onugxjdzrp ghbmpuxwva (lvaenlqojr ) View more	-	01 Jan 2009
				PEG solution and simethicone	(edgihoxqse) = llcnktbxye ghbmpuxwva (lvaenlqojr ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Simethicone

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation